

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Tognin, S;Richter, A;Kempton, MJ;Modinos, G;Antoniades, M;Azis, M;Allen, P;Bossong, MG;Perez, J;Pantelis, C;Nelson, B;Amminger, P;Riecher-Rössler, A;Barrantes-Vidal, N;Krebs, MO;Glenthøj, B;Ruhrmann, S;Sachs, G;Rutten, BPF;De Haan, L;Van Der Gaag, M;Mcguire, P;Valmaggia, LR;Calem, M;Pisani, S;Velthorst, E;Kraan, TC;Van Dam, DS;Burger, N;Mcgorry, P;Politis, A;Goodall, J;Borgwardt, S;Studerus, E;Bressan, R;Gadelha, A;Brietzke, E;Asevedo, G;Asevedo, E;Zugman, A;Domínguez-Martínez, T;Racciopi, A;Kwapil, TR;Monsonet, M;Hinojosa, L;Kazes, M;Daban, C;Bourgin, J;Gay, O;Mam-Lam-Fook, C;Nordholm, D;Randers, L;Krakauer, K;Glenthøj, L;Nordentoft, M;Gebhard, D;Arnhold, J;Klosterkötter, J;Lasser, I;Winklbaur, B;Aschauer, H;Delespaul, PA;Van Os, J;Mcguire, P

Title:

The Relationship Between Grey Matter Volume and Clinical and Functional Outcomes in People at Clinical High Risk for Psychosis

Date:

2022-01-01

Citation:

Tognin, S., Richter, A., Kempton, M. J., Modinos, G., Antoniades, M., Azis, M., Allen, P., Bossong, M. G., Perez, J., Pantelis, C., Nelson, B., Amminger, P., Riecher-Rössler, A., Barrantes-Vidal, N., Krebs, M. O., Glenthøj, B., Ruhrmann, S., Sachs, G., Rutten, B. P. F., ... Mcguire, P. (2022). The Relationship Between Grey Matter Volume and Clinical and Functional Outcomes in People at Clinical High Risk for Psychosis. *Schizophrenia Bulletin Open*, 3 (1), pp.sgac040-. <https://doi.org/10.1093/schizbullopen/sgac040>.

Persistent Link:

<https://hdl.handle.net/11343/316616>

License:

[CC BY-NC](#)

The Relationship Between Grey Matter Volume and Clinical and Functional Outcomes in People at Clinical High Risk for Psychosis

Stefania Tognin^{*1,2,22,⊕}, Anja Richter^{1,22,⊕}, Matthew J. Kempton^{1,3}, Gemma Modinos^{1,⊕}, Mathilde Antoniades¹, Matilda Azis^{1,⊕}, Paul Allen^{1,4}, Matthijs G. Bossong¹, Jesus Perez⁵, Christos Pantelis^{6,⊕}, Barnaby Nelson^{7,8}, Paul Amminger^{7,8}, Anita Riecher-Rössler^{9,⊕}, Neus Barrantes-Vidal^{10,⊕}, Marie-Odile Krebs¹¹, Birte Glenthøj^{12,13}, Stephan Ruhrmann¹⁴, Gabriele Sachs^{15,⊕}, Bart P. F. Rutten¹⁶, Lieuwe de Haan¹⁷, Mark van der Gaag^{18,19}, EU-GEI High Risk Study Group²¹, Lucia R. Valmaggia²⁰, and Philip McGuire^{1,3}

¹Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK; ²South London and Maudsley NHS Foundation Trust, London, UK; ³National Institute for Health Research (NIHR) Biomedical Research Centre (BRC), UK; ⁴Department of Psychology, University of Roehampton, London, UK; ⁵CAMEO Early Intervention in Psychosis Services, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK; ⁶Department of Psychiatry, Melbourne Neuropsychiatry Centre, University of Melbourne & Melbourne Health, Carlton South, Victoria, Australia; ⁷Orygen, Parkville, Victoria, Australia; ⁸Centre for Youth Mental Health, The University of Melbourne, Parkville, Victoria, Australia; ⁹University of Basel, Faculty of Medicine, Basel, Switzerland; ¹⁰Departament de Psicologia Clínica i de la Salut (Universitat Autònoma de Barcelona), Fundació Sanitària Sant Pere Claver (Spain), Center for Biomedical Research in Mental Health (CIBERSAM), Madrid, Spain; ¹¹University of Paris, GHU-Paris, Sainte-Anne, C'JAAD, Hospitalo-Universitaire department SHU, Inserm U1266, Institut de Psychiatrie (CNRS 3557), Paris, France; ¹²Center for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Services Capital Region of Denmark, Mental Health Center Glostrup, Glostrup, Denmark; ¹³Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; ¹⁴Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital University of Cologne, Cologne, Germany; ¹⁵Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; ¹⁶Department of Psychiatry and Neuropsychology, Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience (MHENS), Maastricht University, Maastricht, The Netherlands; ¹⁷Early Psychosis Department, Amsterdam UMC, Amsterdam, The Netherlands; ¹⁸Department of Clinical Psychology and Amsterdam Public Mental Health Research Institute, Faculty of Behavioural and Movement Sciences, VU University, Amsterdam, The Netherlands; ¹⁹Department of Psychosis Research, Parnassia Psychiatric Institute, The Hague, The Netherlands; ²⁰Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK; ²¹See Appendix for EU-GEI High Risk Study Group Author list.; ²²These authors equally contributed to this work.

*To whom correspondence should be addressed; Room M5.09, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, Room M5.09, PO Box 67, De Crespigny Park, London SE5 8AF, UK; tel: +44 (0)20 7848 0415, fax: +44 (0)20 7848 0976; e-mail: Stefania.tognin@kcl.ac.uk

Objective: To examine the association between baseline alterations in grey matter volume (GMV) and clinical and functional outcomes in people at clinical high risk (CHR) for psychosis.

Methods: 265 CHR individuals and 92 healthy controls were recruited as part of a prospective multi-center study. After a baseline assessment using magnetic resonance imaging (MRI), participants were followed for at least two years to determine clinical and functional outcomes, including transition to psychosis (according to the Comprehensive Assessment of an At Risk Mental State, CAARMS), level of functioning (according to the Global Assessment of Functioning), and symptomatic remission (according to the CAARMS). GMV was measured in selected cortical and subcortical regions of interest (ROI) based on previous studies (ie orbitofrontal

gyrus, cingulate gyrus, gyrus rectus, inferior temporal gyrus, parahippocampal gyrus, striatum, and hippocampus). Using voxel-based morphometry, we analysed the relationship between GMV and clinical and functional outcomes.

Results: Within the CHR sample, a poor functional outcome (GAF < 65) was associated with relatively lower GMV in the right striatum at baseline ($P < .047$ after Family Wise Error correction). There were no significant associations between baseline GMV and either subsequent remission or transition to psychosis.

Conclusions: In CHR individuals, lower striatal GMV was associated with a poor level of overall functioning at follow-up. This finding was not related to effects of

antipsychotic or antidepressant medication. The failure to replicate previous associations between GMV and later psychosis onset, despite studying a relatively large sample, is consistent with the findings of recent large-scale multi-center studies.

Key words: clinical high risk for psychosis/clinical outcomes/functioning/remission/transition to psychosis/grey matter volume/structural magnetic resonance imaging

Introduction

A key research goal in studies of people at Clinical High Risk (CHR) for psychosis is to identify measures that could help to predict clinical and functional outcomes in this population. Grey matter volume (GMV) at presentation, as assessed using Magnetic Resonance Imaging (MRI), was the first biological metric to be assessed in this population, and over the last 20 years, several studies have investigated the relationship between baseline GMV and clinical outcomes in CHR samples.^{1–7} Early studies involved relatively small samples and focused on later transition to psychosis as the sole outcome measure.^{7–9} More recently, multi-center studies included larger samples and expanded outcomes to include remission from the CHR state and level of functioning at follow up.^{10–13} Despite this body of work, findings have been inconsistent, and the extent to which MRI measurements of GMV differ between CHR individuals with distinct clinical outcomes is still unclear.

Although a number of early studies reported that reductions in regional GMV at baseline were associated with the subsequent onset of psychosis, the topographical location of the findings varied. For example, GMV studies comparing CHR who transitioned to those who did not, reported lower volume of the left parahippocampal gyrus,¹ the left anterior cingulate cortex (ACC),⁶ and the bilateral insula,⁴ while other studies did not identify significant associations,^{2,3} and some found increases in hippocampal volume.⁵ Similarly, among more recent larger scale studies, while some have described a relationship between lower regional GMV at presentation and later transition,¹ others have not.¹⁴

Relatively few MRI studies have examined associations between baseline GMV and other clinically meaningful outcomes in CHR cohorts, such as level of functioning at follow up or remission from the CHR state. A poor functional outcome has been linked to reduced frontal, limbic, and cerebellar,¹⁵ frontal, cingulate, and temporal,¹³ and striatal GMV at baseline.¹⁶ Nonremission from the CHR state has been associated with reduced GMV in frontal, cingulate and temporal cortex,^{13,15} and in orbitofrontal cortex and the pallidum.¹⁷ A longitudinal study found that nonremission was related to a greater decline in CA1 volume, a hippocampal subfield, which was further associated with increasing symptom severity

over time.¹⁸ However, McIntosh and colleagues¹⁹ found no differences in brain structure (either at baseline or over time) between those CHR individuals who were still experiencing symptoms at follow-up and those who were not. This latter study involved relatives who were at genetic risk for developing schizophrenia, and it is possible that GMV differences observed in other studies might have been driven by different underlying psychopathological mechanisms.

In order to clarify the relationship between GMV in CHR individuals and adverse outcomes, we used MRI to assess a large sample of people at CHR, who were followed up clinically for at least two years to determine outcomes defined in terms of transition to psychosis, level of functioning, and remission from the CHR state. Participants were assessed at nine international sites using the same acquisition sequence (Alzheimer's Disease Neuroimaging Initiative [ADNI] sequence).^{20,21} We adopted a Region of Interest approach (ROIs) to investigate whether GMV of CHR individuals was associated with transition to psychosis (transition vs nontransition, CHR-T vs CHR-NT), level of functioning (good vs poor functioning, CHR-PF vs CHR-GF), and symptomatic remission (remission vs nonremission, CHR-R vs CHR-NR). Based on findings from the studies discussed above,^{1,13,15–18} we hypothesized that transition to psychosis, poor functioning, and nonremission would be associated to decreased GMV within our selected ROIs. Based on mostly inconsistent findings for these outcomes, in each case, we tested the null hypothesis that GMV at baseline would not be related to each outcome at follow up. Most of the selected ROIs were based on prior studies on our outcomes of interest, however, as (1) imaging correlates of functional outcome and symptom remission are relatively new areas of research and (2) the current sample size did not allow for a full agnostic approach, we decided to also explore brain regions in which volumetric differences have been observed between CHR and healthy controls (HC). The final list of ROIs comprised the following: orbitofrontal gyrus, cingulate gyrus, gyrus rectus, inferior temporal gyrus, parahippocampal gyrus, striatum, and hippocampus.^{1,15,16,18,22,23} For completeness, we are also reporting GMV differences between the CHR-T and CHR-NT, CHR-PF and CHR-GF, and CHR-NR and CHR-R subgroups at the whole brain level and GMV differences between the CHR and HC subgroups within the selected ROIs.

Methods

Sample

From July 2010 to August 2015, 234 CHR individuals and 92 HC aged 18–35 years were scanned at nine centers using 3-Tesla MRI scanners and the same ADNI-2 T1 protocol^{20,21} (Amsterdam, the Netherlands; Basel, Switzerland; Cologne, Germany; Copenhagen, Denmark;

London, United Kingdom; Melbourne, Australia; Paris, France; The Hague, the Netherlands; Vienna, Austria) as part of the EU-GEI High Risk Study²⁰ (see [Table S1](#)). The London site included an additional 31 CHR individuals recruited as part of another study and scanned with the same scanner and sequence. Participants recruited in Amsterdam and The Hague were scanned at the same center in Amsterdam, thus they were merged and considered as one site. The final sample comprised 265 individuals at CHR. To reduce variability introduced by small samples, we only included sites that contributed neuroimaging data for at least five CHR participants. Scanner information, details of the image acquisition sequence at each site, and information on included CHR individuals at each site for each analysis are reported in [Supplemental Tables S1 and S2](#).

Exclusion criteria for all participants were past or present diagnosis of neurological disorders according to DSM-IV criteria,²⁴ estimated IQ lower than 60, or any MRI contraindication such as presence of metal implants, pacemakers, or pregnancy. In addition, CHR were excluded if they had a past or present diagnosis of psychotic disorder. HC were excluded if they were meeting CHR criteria, or if they had personal or familiar history of a psychiatric disorder according to DSM-IV criteria.²⁴

Ethical approval for the study was obtained separately at each individual site and informed written consent was obtained from all the participants at the single centers. The study was conducted in accordance with the Declaration of Helsinki.

Clinical Assessment

CHR individuals were defined and assessed using the Comprehensive Assessment of At Risk Mental State (CAARMS²⁵). CHR individuals were included if they were meeting at least one of the following criteria: (1) Attenuated Psychotic Symptoms (APS), subthreshold frequency, and/or subthreshold intensity; (2) Brief Limited Intermittent Psychotic Symptoms (ie positive psychotic symptoms at psychotic intensity and frequency which last for less than 7 days and resolved spontaneously); (3) positive family history for psychosis or schizotypal personality disorder plus chronic low functioning (<50) or a marked decline (ie 30% drop) in psychosocial functioning over the past 12 months (Genetic Risk and Deterioration Syndrome: GRD) as assessed with the SOFAS.²⁶ At baseline, all participants were assessed by trained raters using the CAARMS,²⁵ the Global Assessment of Functioning (GAF²⁷), and the SOFAS.²⁶ Raters were trained in the use of the CAARMS and GAF prior to the study and completed online training videos every 12 months from study onset to assess interrater reliability (see [Supplemental Methods, Table S3](#)). When assessing CAARMS and GAF at follow-up,

the timeframe considered was the time since the last follow-up. Data on baseline demographic characteristics such as age, sex, and ethnicity were obtained from the Medical Research Council Sociodemographic Schedule.²⁸ The presence of psychosis and other Axis I comorbidities was assessed using the SCID-I.²⁹ An estimate of the IQ was measured using the shortened version of the Wechsler Adult Intelligence Scale.^{30,31}

Participants were invited for face-to-face follow-up assessments at 6 months, 1 year, and 2 years after baseline. Where face-to-face meetings were not possible, participants were followed up for 2 years using available clinical records, and this follow-up was extended when additional clinical data was available. Transition to psychosis was determined using the CAARMS²⁵ and the SCID-I,²⁹ with the clinical diagnosis of a psychotic disorder confirmed by the participant's clinical team. Level of functioning was assessed using the GAF scale.²⁷ Remission from the CHR state was defined as when an individual no longer met CAARMS inclusion criteria at the last follow-up assessment available.

Data Analysis

Demographic and Clinical Data. Demographic and clinical data were analyzed using SPSS, version 25.0 (IBM Corp.). Group differences were investigated using t-test for continuous variables and χ^2 test for categorical variables.

MRI Preprocessing. Voxel Based Morphometry (VBM) as implemented in the Statistical Parametric Mapping software (SPM12; <http://www.fil.ion.ucl.ac.uk/spm>) was employed to investigate GMV differences between groups. First, all structural images were visually checked for artifacts, and poor-quality images were excluded. Assessment of image quality resulted in the exclusion of three participants (one with large congenital cyst, one with distortion from brace, one with movement artefact). Second, T1 images were preprocessed with a unified segmentation procedure³² implemented in SPM12. All images were segmented into grey matter (GM), white matter (WM), and cerebrospinal fluid (CSF) partitions. Subsequently, a fast diffeomorphic image registration algorithm (DARTEL) was used to warp the GM partitions into a new study-specific reference space with an isotropic spatial resolution of 1.5 mm³.^{33–35} The warped grey partitions were then affine transformed into the Montreal Neuroanatomical Imaging (MNI) space. An additional “modulation” step³⁶ was used to scale the grey matter probability values by the Jacobian determinants of the deformations to ensure that the total amount of grey matter in each voxel was conserved after the registration. As a final step, the grey matter probability values were smoothed using an 8 mm full-width at half-maximum (FWHM) Gaussian kernel. Proportional scaling of the total intracranial volume was

used to identify regionally specific changes that were not confounded by global differences.

ROI Analysis

An ROI approach was used to investigate group differences in a priori brain areas in which volumetric abnormalities have been identified in previous studies on remission, functional outcomes, and comparisons of CHR individuals and HC. These comprised sets of bilateral cortical and subcortical regions which were examined in two anatomical masks. The first mask included the following cortical regions: orbitofrontal gyrus, cingulate gyrus, gyrus rectus, inferior temporal, and parahippocampal cortex.^{1,22,23} The second included the following subcortical regions: the hippocampus and the striatum (ie caudate, pallidum, putamen).^{15,16,18} The masks were created using the WFU Pickatlas toolbox implemented in SPM12. As these regions of interest covered a large portion of the brain, which would require a very conservative correction for multiple comparisons, we decided to use each mask individually, and then as a merged single mask.

A small volume correction for ROI analyses was applied. Within the masks, statistical inferences were made using a threshold of $P < .05$ after Family-Wise Error (FWE) correction for multiple comparisons. In all analyses, scanning site, age, and sex were modeled as covariates of no interest. Ethnicity was added as a covariate of no interest in the comparison between HC and CHR as there was a significant difference between groups. Results at $P < .001$ uncorrected are not reported in the main text but are available in the supplemental material.

Clinical and Functional Outcomes at Follow-up

In order to examine MRI correlates of transition to psychosis, functional outcome, and clinical remission we performed three full factorial analyses of co-variance (ANCOVA). In the first ANCOVA, CHR individuals who had transitioned to psychosis during follow-up (CHR-T) were compared to CHR individuals who did not transition to psychosis (CHR-NT). In the second ANCOVA we compared CHR individuals with a relatively good or poor level of functioning at the last available follow-up assessment for that participant. Following previous studies in CHR samples,³⁷⁻⁴⁰ a GAF score of 65 or more at follow-up was used as the threshold for a good functional outcome (CHR-GF), with a score below 65 defined as poor (CHR-PF). A third ANCOVA compared CHR individuals who still met CAARMS criteria at the last available follow-up (nonremission, CHR-NR) with CHR individuals who did not (remission, CHR-R). ROI analyses were then applied to the results of these ANCOVAs.

For completeness, we reported GMV differences between the CHR-T and CHR-NT, CHR-PF and CHR-GF, and CHR-NR and CHR-R subgroups at the whole brain level, in the [Supplementary Materials \(3. Supplemental results\)](#). GMV differences between CHR and HC within the selected ROIs are also reported in the [Supplementary Materials \(3. Supplemental results\)](#). In all analyses, scanning site, age, and sex were modeled as covariates of no interest.

In order to exclude that significant results were confounded by the use of antipsychotic or antidepressant medication or substance use (ie cannabis) we run two additional analyses. Firstly, as the number of participants taking antipsychotic medication was relatively low ($N = 28$), we rerun all the analyses removing these participants. Secondly, as the number of participants taking antidepressants or using cannabis was relatively high ($N = 81$ and $N = 90$), we modeled these as covariates of no interest. Results are reported in [Supplementary Materials](#).

Results

Demographic and Clinical Data

Of the 262 CHR individuals studied at baseline (after excluding 3 participants due to poor quality of images), 234 (89.3%) were antipsychotic medication-naïve, 28 (10.7%) were taking antipsychotic medication and 81 (30.9%) were taking antidepressants. During the follow up period, 51 participants (19%) transitioned to psychosis (CHR-T), and 211 (81%) did not (CHR-NT). The mean time from baseline to transition in those individuals who transitioned to psychosis was 360.1 (SD = 409.9 days). Of the 164 CHR individuals for whom GAF data was available at the latest possible follow-up (mean time: 11.92 months [SD = 6.66 months], 63 had a good functional outcome (38%, CHR-GF, mean score at follow-up: 73.23 [SD = 7.44], mean time: 13.50 months [SD = 7.33 months]) and 101 had a poor outcome (62%, CHR-PF, mean score at follow-up: 52.02 [SD = 9.69], mean time: 10.96 months [SD = 6.06 months]). Information on remission was available for 133 individuals, of which 57 were in remission (43%, CHR-R) at follow up and 76 still met CHR criteria (57%, CHR-NR). The characteristics of these subgroups are shown in [table 1](#). There were no significant differences between the CHR-PF and CHR-GF, CHR-NR and CHR-R, and the CHR-T and CHR-NT subgroups or between CHR individuals and HC in age, sex, or handedness. However, the CHR-PF subgroup had a significantly lower baseline GAF score than the CHR-GF subgroup ($P = .01$). In addition, compared to HC, CHR individuals completed significantly fewer years of education ($P < .001$), and differed in terms of ethnicity ($P < .001$; see [table 2](#)). Finally, significantly more CHR-NT individuals ($n = 15$) were taking antipsychotic

Table 1. Baseline Demographic and Clinical Characteristics of Participants

	CHR-NT (n = 211)	CHR-T (n = 51)	P Value	CHR-GF (n = 63)	CHR-PF (n = 101)	P Value	CHR-R (n = 57)	CHR-NR (n = 76)	P Value
Sex, N									
Male	109	29	.50	29	55	.29	30	37	.65
Female	102	22		34	46		27	39	
Age in years, mean (SD)	22.7 (4.8)	22.3 (4.0)	.60	22.4 (4.1)	23.2 (5.1)	.31	23.0 (4.1)	23.4 (5.5)	.64
Education in years, mean (SD)	14.6 (2.9)	14.0 (3.0)	.30	15.1 (2.7)	14.7 (3.2)	.44	15.5 (2.7)	14.8 (3.0)	.18
Ethnicity									
Caucasian	154	37	.73	50	70	.55	38	54	.34
Black	20	7		5	15		10	7	
Asian	3	1		1	2		0	2	
Others	34	6		8	14		9	13	
Handedness									
Right	127	32	.42	42	68	.06	42	54	.52
Left	20	3		9	5		6	11	
Baseline GAF score, mean (SD)	54.7 (9.9)	52.7 (9.1)	.31	56.6 (10.3)	52.8 (9.1)	.01	55.2 (9.1)	54.8 (9.5)	.81
Antipsychotic medication, N									
Yes	15	13	<.001	3	11	.17	5	5	.64
No	196	38		60	90		52	71	
Antidepressant medication, N									
Yes	68	13	.35	22	30	.49	23	22	.17
No	143	38		41	71		34	54	
Cannabis, N									
Yes	74	16	.89	22	32	.88	23	14	.06
No	128	29		42	74		35	39	
Days to transition, mean (SD)	—	360.1 (409.9)	NA	—	—	—	—	—	—

Note: CHR, clinical high risk; CHR-GF, clinical high risk with good overall functioning (GAF ≥ 65); CHR-NR, clinical high risk non-remission; CHR-NT, clinical high risk non-transition; CHR-PF, clinical high risk with poor overall functioning (GAF < 65); CHR-R, clinical high risk remission; CHR-T, clinical high risk transition; GAF, Global Assessment of Functioning Scale (range: 0–100), the lower the score the more impaired overall functioning; NA, not available; SD, standard deviation. Significant differences are highlighted in bold.

medication at baseline compared to CHR-T individuals ($n = 13$, $P < .001$).

MRI Results

GMV and Transition to Psychosis. The ROI analyses found no significant differences between the CHR-T ($n = 51$) and CHR-NT ($n = 211$) subgroups ($P < .05$, FWE-corrected threshold). Results did not change after removing CHR participants on antipsychotic medication or adjusting for antidepressant medication use or cannabis use. Differences evident at a threshold of $P < .001$ uncorrected are reported in the supplementary results. No differences were found at the whole brain level.

GMV and Functional Outcome. Subcortical mask: compared to the CHR-GF subgroup ($n = 63$), the CHR-PF subgroup ($n = 101$) had less GMV in the right striatum (Montreal Neurological Institute [MNI] coordinates $x = 6$, $y = 20$, $z = -3$, z score = 3.79, $k = 186$, $P = .047$ FWE-corrected threshold; see [figure 1](#)). After excluding individuals that were taking antipsychotic medication (CHR-GF = 3; CHR-PF = 11), the significant effect in the right striatum remained unchanged (MNI coordinates $x = 6$, $y = 20$, $z = -3$, z score = 3.84, $k = 246$, $P = .040$ FWE-corrected). Antidepressant medication and cannabis use did not influence the finding in the right striatum.

Cortical and merged masks: no significant GMV differences were found ($P < .05$, FWE-corrected threshold). No differences were found at the whole brain level.

GMV and Remission From the CHR State. The ROI analyses showed no significant differences between the CHR-NR ($n = 76$) and CHR-R subgroups ($n = 57$) ($P < .05$, FWE-corrected threshold). Findings remained unchanged after removing CHR individuals on antipsychotics or adjusting for antidepressant or cannabis use. No differences were found at the whole brain level.

Discussion

The main finding from the present study was that a smaller right striatal GMV at baseline was associated with a relatively poor functional outcome in CHR individuals. However, we did not find evidence that alterations in GMV at baseline were linked to either later onset of psychosis or to remission from the CHR state.

An association between altered striatal volume and functional outcome in people at high risk for psychosis

Table 2. Baseline Demographic and Clinical Characteristics of the Whole CHR Sample and Healthy Controls

	Healthy Control Group ($n = 92$)	CHR Group ($n = 262$)	<i>P</i> Value
Sex, <i>N</i>			
Male	47	138	.083
Female	45	124	
Age in years, mean (SD)	23.7 (4.2)	22.6 (4.8)	.09
Education in years, mean (SD)	16.0 (2.9)	14.6 (2.9)	<.001
Ethnicity			
Caucasian	65	191	<.001
Black	10	27	
Asian	11	4	
Others	6	40	
Antipsychotic medication, <i>N</i>			
Yes	0	28	NA
No	92	234	
Antidepressant medication, <i>N</i>			
Yes	0	81	NA
No	92	181	
Cannabis use, <i>N</i>			
Yes	25	90	.96
No	43	157	
Handedness			
Right	66	159	.28
Left	6	23	

Note: CHR, clinical high risk; NA, not available; SD, standard deviation.

Significant differences are highlighted in bold.




Fig. 1. Differences between clinical high risk individuals with poor overall functioning (CHR-PF) and those with good overall functioning (CHR-GF). The CHR-PF group had less grey matter volume than did CHR-GF in the right striatum ($P < .05$ FWE-corrected). Effects are displayed at $P < .001$ uncorrected for illustration purposes. T-values are indicated by color bars (for color figure refer to online version).

is consistent with data from previous studies. De Wit and colleagues¹⁶ found that lower baseline subcortical volumes predicted long-term level of functioning in CHR individuals. Eggers and colleagues⁴¹ reported that young people presenting with depressive, manic, and psychotic symptoms had reduced caudate volume relative to healthy controls, and that this was correlated with impaired functioning. A recent multi-center MRI study in 116 CHR individuals also found an association between GMV at baseline and functional outcome.¹⁰ However, the relationship found in this study, was with cortical rather than the striatal volume, and was specific to the level of social, as opposed to overall functioning. Finally, studies using other neuroimaging modalities in CHR individuals have previously linked a poor functional outcome to increased prefrontal and striatal activation, to lower thalamic glutamate levels,⁴⁰ and to altered interactions between hippocampal resting activity and striatal dopamine synthesis capacity.³⁸

Level of functioning is increasingly used as an outcome measure in studies of CHR individuals, as it is clinically meaningful and complements other outcomes such as transition to psychosis and remission, which primarily depend on measurements of symptom severity.^{42,43} In particular, some individuals who, from a symptomatic perspective, may be categorized as having a relatively good outcome can still have a very low level of overall functioning, which translates into a high level of clinical need.¹² However, because it has only been employed as an outcome measure relatively recently, its biological basis in CHR individuals is still poorly understood.

A number of previous MRI studies have reported associations between later transition to psychosis and altered GMV in cortical brain regions, thalamus, hippocampus, and basal ganglia,^{1,4-7,44-46} while other studies have not found a significant relationship.^{2,3,37,47} Early MRI studies in CHR groups involved relatively small samples, and the number of individuals in the subgroup that developed psychosis was even smaller. More recent studies have been able to examine larger samples by recruiting from multiple sites. However, the findings have again been inconsistent. One previous multi-center study utilizing a relatively large sample was conducted by Mechelli and colleagues.¹ The study assessed $n = 182$ CHR individuals and reported an association between later transition and reduced parahippocampal volume. Participants were scanned at five sites, with each using a different protocol, and all but one acquiring data at 1.5T which might have led to different findings compared to those reported here. However, more recently, Cannon and colleagues,¹⁴ in a study of $n = 274$ individuals, found no relationship between MRI measures at baseline and later transition. These data were collected at eight sites, all using the same ADNI protocol at 3T.²¹ It is possible that different acquisitions sequences and scanner manufacturers might have led to different results.⁴⁸ It is also possible that

differences in participant recruitment and hence clinical characteristics of an already very heterogeneous population might have led to different results.⁴⁸ Only a few MRI studies have investigated a relation between GMV and nonremission from the CHR state, showing reduced volumes in frontal, cingulate, temporal cortex,¹³ in the orbitofrontal cortex, pallidum,¹⁷ and CA1,¹⁸ while another study, consistent with our present findings, found no significant association.¹⁹

In the present study, because the total number of participants was relatively large, and the numbers in the respective outcome subgroups were medium size (ranging 37–192), the absence of significant associations with transition and remission seems unlikely to simply be due to a lack of power. Nevertheless, although our participants all met the same inclusion and exclusion criteria, the CHR state is an intrinsically heterogeneous category.⁴⁹ While all participants were assessed at presentation, individuals may contact clinical services at different stages of the CHR state. In an effort to reduce and control the heterogeneity within the CHR state, some recent studies modified the standard inclusion criteria, such that samples are enriched for individuals with a particularly high risk of transition.^{48,50} Because some of the sites in the present study contributed a relatively small number of individuals, we could not model site as factor, but controlled for site variability by increasing the number of covariates of no interest. The latter approach might have reduced the chance of detecting small yet significant effects.

Strengths and Limitations

A methodological strength of the present study is that all sites acquired MRI data using the same ADNI-2 protocol,²¹ which was specifically designed for multi-center studies. Nevertheless, variability can still arise through the use of scanners that differ in manufacturer, model, and age.^{51,52} This can be assessed by scanning a group of the same “travelling” volunteers at each site,^{52,53} with post-hoc calibration methods used to attenuate these effects.⁴⁸ However, this was not possible in the present study.

A further strength is that we minimized the potentially confounding impact of site differences by restricting the analysis to those sites that had contributed imaging data from at least five CHR individuals. Although this led to the exclusion of one site in the functional (5 individuals excluded) and one site in the remission analyses (2 individuals excluded) (see [Supplementary Materials](#)), this approach is likely to have increased the power to detect true statistical effects, and by including a moderate number of covariates have reduced the risk of Type II errors.⁵⁴⁻⁵⁶

During the follow up period, as is typical for CHR individuals, participants received needs-based clinical care involving case management, but in most cases

(89.3%) not any active treatment (such as antipsychotic medication). While its content may have varied between sites and individuals, a recent network meta-analysis suggests that there is no evidence that this form of clinical contact significantly alters long term clinical outcomes.⁵⁷

This study has also a number of limitations. Firstly, GAF was used to measure functioning. While GAF is still widely used in research settings, it has been criticized for its lack of reliability⁵⁸ and limited ability to meaningfully assess all areas of functioning (as opposed to eg the WHODAS⁵⁹). To improve reliability within and across EUGEI sites, regular interrater reliability exercises, including key measures such as the CAARMS and the GAF, were carried out before⁶⁰ and throughout the duration of the study. The GAF reliability score in the final year of the study was 0.83, indicating good reliability (see Table S3). Secondly, in the present study we subdivided groups using GAF scores of >65 and <65 as thresholds following the approach used in previous studies in CHR samples.^{37,38,40,61} While we acknowledge that GAF could be analyzed as a continuous variable, an advantage of using the cut-off is that it facilitates comparison of our data with those from with other studies that used the same approach. Thirdly, while longitudinal analyses would be helpful to elucidate the trajectories of our outcomes of interest, the high number of missing outcome data at different follow-up time points did not allow for these analyses to be carried out. Missing data, and consequently reduced sample sizes, are particularly problematic when conducting imaging analyses which require modest to large samples. Finally, while multi-center recruitment is necessary to ascertain large samples, this also increases the possible confounding effects of site differences in MRI acquisition and clinical ratings. However, we minimized the latter by using the same scanning protocol,²¹ and conducting regular interrater reliability exercises both before⁶⁰ and throughout the duration of the study.

Conclusion

Our findings suggest that in people at CHR for psychosis, relatively reduced right striatal volume is associated with a poor functional outcome. The absence of associations with either symptomatic remission or transition to psychosis, despite a relatively large sample size, raises the possibility that other neuroimaging measures⁶²⁻⁶⁵ or peripheral blood markers,^{66,67} might be better predictors of outcomes in CHR individuals, particularly when these are integrated in multi-modal models.⁶⁸ We plan to investigate this in further studies in the EU-GEI sample.

Supplementary Data

Supplementary data are available at *Schizophrenia Bulletin* Open online.

Funding

The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project is funded by grant agreement HEALTH-F2-2010-241909 (Project EU-GEI) from the European Community Seventh Framework Programme. Additional support was provided by a Medical Research Council Fellowship to M.K. (grant MR/J008915/1). G.M. is supported by a Sir Henry Dale Fellowship, jointly funded by the Wellcome Trust and the Royal Society (202397/Z/16/Z). C.P. was supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1105825), NHMRC L3 Investigator Grant (1196508). B.N. was supported by an NHMRC Senior Research Fellowship (1137687) and a University of Melbourne Dame Kate Campbell Fellowship. The Melbourne site was supported by NHMRC-EU Grant (ID: 567215). N.B.V. was supported by Ministerio de Ciencia, Innovación e Universidades (PSI2017-87512-C2-1-R).

Acknowledgments

We would like to thank all participants who took part in the study.

Conflict of Interest

None.

Appendix

*EU-GEI High Risk Study Group Author

Philip McGuire^{1,3}
 Lucia R. Valmaggia²⁰
 Maria Calem¹
 Mathilde Antoniadou¹
 Sara Pisani¹
 Gemma Modinos¹
 Lieuwe de Haan¹⁷
 Mark van der Gaag^{18,19}
 Eva Velthorst¹⁷
 Tamar C. Kraan¹⁷
 Daniella S. van Dam¹⁷
 Nadine Burger¹⁷
 Barnaby Nelson^{7,8}
 Patrick McGorry^{7,8}
 G Paul Amminger^{7,8}
 Christos Pantelis⁶
 Athena Politis⁷
 Joanne Goodall⁷
 Anita Riecher-Rössler⁹
 Stefan Borgwardt⁹
 Erich Studerus⁹
 Rodrigo Bressan²³
 Ary Gadelha²³

Elisa Brietzke²³
 Gracielle Asevedo²³
 Elson Asevedo²³
 Andre Zugman²³
 Neus Barrantes-Vidal¹⁰
 Tecelli Domínguez-Martínez¹⁰
 Anna Racciopi¹⁰
 Thomas R. Kwapił¹⁰
 Manel Monsonet¹⁰
 Lúdia Hinojosa¹⁰
 Mathilde Kazes¹¹
 Claire Daban¹¹
 Julie Bourgin¹¹
 Olivier Gay¹¹
 Célia Mam-Lam-Fook¹¹
 Marie-Odile Krebs¹¹
 Dorte Nordholm¹²
 Lasse Randers¹²
 Kristine Krakauer¹²
 Louise Glenthøj¹²
 Birte Glenthøj^{12,13}
 Merete Nordentoft¹²
 Stephan Ruhrmann¹⁴
 Dominika Gebhard¹⁴
 Julia Arnhold¹⁴
 Joachim Klosterkötter¹⁴
 Gabriele Sachs¹⁵
 Iris Lasser¹⁵
 Bernadette Winklbaur¹⁵
 Harald Aschauer¹⁵
 Philippe A Delespaul¹⁶
 Bart P. Rutten¹⁶
 Jim van Os^{1,16}

²³LiNC - Lab Interdisciplinar Neurociências Clínicas,
 Depto Psiquiatria, Escola Paulista de Medicina,
 Universidade Federal de São Paulo – UNIFESP.

References

- Mechelli A, Riecher-Rossler A, Meisenzahl EM, *et al.* Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. *Arch Gen Psychiatry* 2011;68(5):489–495.
- Yucel M, Wood SJ, Phillips LJ, *et al.* Morphology of the anterior cingulate cortex in young men at ultra-high risk of developing a psychotic illness. *Br J Psychiatry* 2003;182:518–524.
- Velakoulis D, Wood SJ, Wong MT, *et al.* Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. *Arch Gen Psychiatry* 2006;63(2):139–149.
- Takahashi T, Wood SJ, Yung AR, *et al.* Insular cortex gray matter changes in individuals at ultra-high-risk of developing psychosis. *Schizophr Res* 2009;111(1–3):94–102.
- Buehlmann E, Berger GE, Aston J, *et al.* Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study. *J Psychiatr Res* 2010;44(7):447–453.
- Rothlisberger M, Riecher-Rossler A, Aston J, Fusar-Poli P, Radu EW, Borgwardt S. Cingulate volume abnormalities in emerging psychosis. *Curr Pharm Des* 2012;18(4):495–504.
- Pantelis C, Velakoulis D, McGorry PD, *et al.* Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. *Lancet* 2003;361(9354):281–288.
- Borgwardt SJ, McGuire PK, Aston J, *et al.* Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. *Br J Psychiatry Suppl* 2007;51:s69–s75.
- Borgwardt SJ, McGuire PK, Aston J, *et al.* Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. *Schizophr Res* 2008;106(2-3):108–114.
- Koutsouleris N, Kambertz-Illankovic L, Ruhrmann S, *et al.* Prediction models of functional outcomes for individuals in the clinical high-risk state for psychosis or with recent-onset depression: a multimodal, multisite machine learning analysis. *JAMA Psychiatry* 2018;75(11):1156–1172.
- Addington J, Cornblatt BA, Cadenhead KS, *et al.* At clinical high risk for psychosis: outcome for nonconverters. *Am J Psychiatry* 2011;168(8):800–805.
- Rutigliano G, Valmaggia L, Landi P, *et al.* Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra high risk for psychosis. *J Affect Disord* 2016;203:101–110.
- Cropley VL, Lin A, Nelson B, *et al.* Baseline grey matter volume of non-transitioned “ultra high risk” for psychosis individuals with and without attenuated psychotic symptoms at long-term follow-up. *Schizophr Res* 2016;173(3):152–158.
- Cannon TD, Chung Y, He G, *et al.* Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. *Biol Psychiatry* 2015;77(2):147–157.
- Reniers RL, Lin A, Yung AR, *et al.* Neuroanatomical predictors of functional outcome in individuals at ultra-high risk for psychosis. *Schizophr Bull* 2017;43(2):449–458.
- de Wit S, Ziermans TB, Nieuwenhuis M, *et al.* Individual prediction of long-term outcome in adolescents at ultra-high risk for psychosis: applying machine learning techniques to brain imaging data. *Hum Brain Mapp* 2017;38(2):704–714.
- de Wit S, Wierenga LM, Oranje B, *et al.* Brain development in adolescents at ultra-high risk for psychosis: longitudinal changes related to resilience. *Neuroimage Clin* 2016;12:542–549.
- Ho NF, Holt DJ, Cheung M, *et al.* Progressive decline in hippocampal CA1 volume in individuals at ultra-high-risk for psychosis who do not remit: findings from the longitudinal youth at risk study. *Neuropsychopharmacology* 2017;42(6):1361–1370.
- McIntosh AM, Owens DC, Moorhead WJ, *et al.* Longitudinal volume reductions in people at high genetic risk of schizophrenia as they develop psychosis. *Biol Psychiatry* 2011;69(10):953–958.
- van Os J, Rutten BP, *et al.*; European Network of National Networks studying Gene-Environment Interactions in Schizophrenia (EU-GEI). Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. *Schizophr Bull* 2014;40(4):729–736.

21. initiative. IAAMaAsdn, available at: <http://adni.loni.usc.edu/methods/mri-tool/mri-acquisition/>. Accessed May 31, 2022.
22. Gong Q, Dazzan P, Scarpazza C, et al. A neuroanatomical signature for schizophrenia across different ethnic groups. *Schizophr Bull* 2015;41(6):1266–1275.
23. Nenadic I, Dietzek M, Schonfeld N, et al. Brain structure in people at ultra-high risk of psychosis, patients with first-episode schizophrenia, and healthy controls: a VBM study. *Schizophr Res* 2015;161(2–3):169–176.
24. Association. AAP. *Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV)*. Washington DC: American Psychiatric Press Inc; 1994.
25. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. *Aust N Z J Psychiatry* 2005;39(11–12):964–971.
26. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. *Am J Psychiatry* 1992;149(9):1148–1156.
27. Hall RC. Global assessment of functioning. A modified scale. *Psychosomatics* 1995;36(3):267–275.
28. Mallett R. *Sociodemographic Schedule*. London, UK: Section of Social Psychiatry, Institute of Psychiatry; 1997.
29. First M, Spitzer R, Gibbon M, Williams J. *Structured Clinical Interview for DSM-IV axis I disorders (SCID)*. New York, NY: New York State Psychiatric Institute Biometrics Research; 1995.
30. Blyler CR, Gold JM, Iannone VN, Buchanan RW. Short form of the WAIS-III for use with patients with schizophrenia. *Schizophr Res* 2000;46(2–3):209–215.
31. Velthorst E, Levine SZ, Henquet C, et al. To cut a short test even shorter: reliability and validity of a brief assessment of intellectual ability in schizophrenia--a control-case family study. *Cogn Neuropsychiatry* 2013;18(6):574–593.
32. Ashburner J, Friston KJ. Unified segmentation. *Neuroimage* 2005;26(3):839–851.
33. Ashburner JA. fast diffeomorphic image registration algorithm. *Neuroimage* 2007;38(1):95–113.
34. Ashburner J, Friston K. Multimodal image coregistration and partitioning--a unified framework. *Neuroimage* 1997;6(3):209–217.
35. Ashburner J, Friston KJ. Computing average shaped tissue probability templates. *Neuroimage* 2009;45(2):333–341.
36. Mechelli A, Price JC, Friston JK, John A. Voxel-based morphometry of the human brain: methods and applications. *Curr Med Imaging Rev* 2005;1:105–113.
37. Modinos G, Kempton MJ, Tognin S, et al. Association of adverse outcomes with emotion processing and its neural substrate in individuals at clinical high risk for psychosis. *JAMA Psychiatry* 2020;77(2):190–200.
38. Modinos G, Richter A, Egerton A, et al. Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes. *Neuropsychopharmacology* 2021;46(8):1468–1474.
39. Bossong MG, Antoniades M, Azis M, et al. Association of hippocampal glutamate levels with adverse outcomes in individuals at clinical high risk for psychosis. *JAMA Psychiatry* 2019;76(2):199–207.
40. Allen P, Chaddock CA, Egerton A, et al. Functional outcome in people at high risk for psychosis predicted by thalamic glutamate levels and prefronto-striatal activation. *Schizophr Bull* 2015;41(2):429–439.
41. Eggs PS, Hatton SN, Hermens DF, Hickie IB, Lagopoulos J. Subcortical volumetric differences between clinical stages of young people with affective and psychotic disorders. *Psychiatry Res Neuroimaging* 2018;271:8–16.
42. Carrion RE, McLaughlin D, Goldberg TE, et al. Prediction of functional outcome in individuals at clinical high risk for psychosis. *JAMA Psychiatry* 2013;70(11):1133–1142.
43. Schmidt A, Cappucciati M, Radua J, et al. Improving prognostic accuracy in subjects at clinical high risk for psychosis: systematic review of predictive models and meta-analytical sequential testing simulation. *Schizophr Bull* 2017;43(2):375–388.
44. Koutsouleris N, Meisenzahl EM, Davatzikos C, et al. Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. *Arch Gen Psychiatry* 2009;66(7):700–712.
45. Koutsouleris N, Borgwardt S, Meisenzahl EM, Bottlender R, Moller HJ, Riecher-Rössler A. Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: results from the FePsy study. *Schizophr Bull* 2012;38(6):1234–1246.
46. Mittal VA, Walker EF, Bearden CE, et al. Markers of basal ganglia dysfunction and conversion to psychosis: neurocognitive deficits and dyskinesias in the prodromal period. *Biol Psychiatry* 2010;68(1):93–99.
47. Hannan KL, Wood SJ, Yung AR, et al. Caudate nucleus volume in individuals at ultra-high risk of psychosis: a cross-sectional magnetic resonance imaging study. *Psychiatry Res* 2010;182(3):223–230.
48. Tognin S, van Hell HH, Merritt K, et al. Towards precision medicine in psychosis: benefits and challenges of multimodal multicenter studies-PSYSCAN: translating neuroimaging findings from research into clinical practice. *Schizophr Bull* 2020;46(2):432–441.
49. Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. *Arch Gen Psychiatry* 2012;69(3):220–229.
50. Addington J, Liu L, Brummitt K, et al. North American Prodrome Longitudinal Study (NAPLS 3): methods and baseline description. *Schizophr Res* 2022;243:262–267.
51. Jovicich J, Czanner S, Han X, et al. MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. *Neuroimage* 2009;46(1):177–192.
52. Schnack HG, van Haren NE, Brouwer RM, et al. Mapping reliability in multicenter MRI: voxel-based morphometry and cortical thickness. *Hum Brain Mapp* 2010;31(12):1967–1982.
53. Cannon TD, Sun F, McEwen SJ, et al. Reliability of neuroanatomical measurements in a multisite longitudinal study of youth at risk for psychosis. *Hum Brain Mapp* 2014;35(5):2424–2434.
54. Vierron E, Giraudeau B. Sample size calculation for multicenter randomized trial: taking the center effect into account. *Contemp Clin Trials* 2007;28(4):451–458.
55. Suckling J, Barnes A, Job D, et al. The neuro/PSYGRID calibration experiment: identifying sources of variance and bias in multicenter MRI studies. *Hum Brain Mapp* 2012;33(2):373–386.
56. Hyatt CS, Owens MM, Crowe ML, Carter NT, Lynam DR, Miller JD. The quandary of covarying: a brief review and empirical examination of covariate use in structural neuroimaging studies on psychological variables. *Neuroimage* 2020;205:116225.
57. Davies C, Cipriani A, Ioannidis JPA, et al. Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. *World Psychiatry* 2018;17(2):196–209.

58. Vatnaland T, Vatnaland J, Friis S, Opjordsmoen S. Are GAF scores reliable in routine clinical use? *Acta Psychiatr Scand* 2007;115(4):326–330.
59. Federici S, Bracalenti M, Meloni F, Luciano JV. World Health Organization disability assessment schedule 2.0: an international systematic review. *Disabil Rehabil* 2017;39(23):2347–2380.
60. Berendsen S, Kapitein P, Schirmbeck F, *et al.* Pre-training inter-rater reliability of clinical instruments in an international psychosis research project. *Schizophr Res* 2021;230:104–107.
61. Bossong MG, Antoniadou M, Azis M, *et al.* Association of hippocampal glutamate levels with adverse outcomes in individuals at clinical high risk for psychosis. *JAMA Psychiatry* 2019;76(2):199–207.
62. Kempton MJ, McGuire P. How can neuroimaging facilitate the diagnosis and stratification of patients with psychosis? *Eur Neuropsychopharmacol* 2015;25(5):725–732.
63. Vieira S, Gong QY, Pinaya WHL, *et al.* Using machine learning and structural neuroimaging to detect first episode psychosis: reconsidering the evidence. *Schizophr Bull* 2020;46(1):17–26.
64. Morgan SE, Young J, Patel AX, *et al.* Functional magnetic resonance imaging connectivity accurately distinguishes cases with psychotic disorders from healthy controls, based on cortical features associated with brain network development. *Biol Psychiatry Cogn Neurosci Neuroimaging* 2021;6(12):1125–1134.
65. Guo S, Huang CC, Zhao W, *et al.* Combining multi-modality data for searching biomarkers in schizophrenia. *PLoS One* 2018;13(2):e0191202.
66. Dickens AM, Sen P, Kempton MJ, *et al.* Dysregulated lipid metabolism precedes onset of psychosis. *Biol Psychiatry* 2021;89(3):288–297.
67. Pollak TA, Kempton MJ, Iyegbe C, *et al.* Clinical, cognitive and neuroanatomical associations of serum NMDAR auto-antibodies in people at clinical high risk for psychosis. *Mol Psychiatry* 2021;26(6):2590–2604.
68. Koutsouleris N, Dwyer DB, Degenhardt F, *et al.* Multimodal machine learning workflows for prediction of psychosis in patients with clinical high-risk syndromes and recent-onset depression. *JAMA Psychiatry* 2021;78(2):195–209.